| Autor: |
Osmanovic Barilar J; Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia., Knezovic A; Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia., Homolak J; Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia., Babic Perhoc A; Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia., Salkovic-Petrisic M; Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia. |
| Abstrakt: |
The incretin system is an emerging new field that might provide valuable contributions to the research of both the pathophysiology and therapeutic strategies in the treatment of diabetes, obesity, and neurodegenerative disorders. This study aimed to explore the roles of central glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) on cell metabolism and energy in the brain, as well as on the levels of these incretins, insulin, and glucose via inhibition of the central incretin receptors following intracerebroventricular administration of the respective antagonists in healthy rats and a streptozotocin-induced rat model of sporadic Alzheimer's disease (sAD). Chemical ablation of the central GIP receptor (GIPR) or GLP-1 receptor (GLP-1R) in healthy and diseased animals indicated a region-dependent role of incretins in brain cell energy and metabolism and central incretin-dependent modulation of peripheral hormone secretion, markedly after GIPR inhibition, as well as a dysregulation of the GLP-1 system in experimental sAD. |
